Teleflex stock reports 28.9 percent Q2 revenue growth today
Teleflex Inc. reported a significant 28.9 percent increase in Q2 2026 revenue, reaching USD 570.3 million, and updated its adjusted EPS guidance for fiscal 2026 to USD 6.90-7.20. Despite this revenue growth, the company's pro forma adjusted constant-currency revenue growth guidance was slightly reduced. Analysts maintain a "Moderate Buy" consensus, with an average target price of USD 155.20, indicating a potential recovery.
Teleflex (TFX) Soars 4.4%: Is Further Upside Left in the Stock?
Teleflex (TFX) shares surged 4.3% due to investor optimism following BofA Securities upgrading the stock to Buy with a higher price target and the appointment of a new medical technology executive to its Board. The company is expected to report Q3 earnings of $1.92 per share, despite a projected decrease in revenue. The stock currently holds a Zacks Rank #1 (Strong Buy), indicating potential for further price appreciation.
Teleflex TFX Stock Steadies As Board And Stent News Build Momentum
Teleflex (TFX) stock has seen a 4.35% increase following positive developments in its medical technology. The company has appointed Sean M. Salmon, former Medtronic executive, to its Board and Growth & Operating Committee, signaling a strategic focus on transformation and operational execution. Additionally, Teleflex showcased its Dynetic-35 stent system at CIRSE 2026, highlighting strong clinical data, though its commercial impact is currently limited as it's unapproved in the U.S.
Why Teleflex (TFX) Stock Is Trading Up Today
Teleflex (TFX) stock jumped 4.5% after BofA Securities upgraded it from Neutral to Buy and raised its price target from $145 to $158. This upgrade signals greater confidence in the company's prospects and attracted buying interest. Despite a significant drop 11 months ago due to underwhelming earnings and a collapse in operating margin, the stock is up 4.1% year-to-date, though still below its 52-week high.
Teleflex stock last trades at USD 127.18 on September 28, 2026
Teleflex shares closed at USD 127.18 on September 28, 2026, marking a 4.19 percent increase. The company recently announced the appointment of Sean M. Salmon to its board of directors and highlighted its Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026. The stent system showed a 100 percent procedural success rate in a study of iliac artery lesions.
Teleflex (NYSE:TFX) Shares Up 3.8% Following Analyst Upgrade
Teleflex (NYSE:TFX) shares increased by 3.8% after Bank of America upgraded the stock from neutral to buy and raised its price target from $145 to $158. The company has a consensus "Moderate Buy" rating from analysts with an average target price of $155.20. Teleflex recently exceeded Q2 earnings expectations with $1.76 EPS and $570.33 million in revenue, and institutional investors own a significant 95.62% of the company's stock.
Zacks Research Upgrades Teleflex (NYSE:TFX) to "Strong-Buy"
Zacks Research has upgraded Teleflex (NYSE:TFX) from a "hold" to a "strong-buy" rating. This upgrade comes after Teleflex reported strong quarterly earnings, beating consensus estimates with an EPS of $1.76 and a 28.9% year-over-year revenue increase to $570.33 million. The company's stock opened 2% higher, and analysts currently maintain a "Moderate Buy" rating with an average price target of $152.90.
Teleflex Inc. stock heads into the open after a market-led decline
Teleflex Inc. stock closed lower on September 24, 2026, mirroring a slight decline in the S&P 500. The article notes the company's stock performance on the NYSE and mentions upcoming market events, including the Baker Hughes oil rig count. This report summarizes the market activity for Teleflex Inc. heading into the next trading session.
Teleflex Incorporated (TFX) Stock forecasts
Argus has lowered its target price for Teleflex Incorporated (TFX) stock to $131.00, down from an unspecified previous target. Teleflex, a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices, is currently trading at $122.07. The report was published on September 23, 2026.
Corient Private Wealth LP Has $2.92 Million Holdings in Teleflex Incorporated $TFX
Corient Private Wealth LP significantly increased its stake in Teleflex Incorporated (NYSE:TFX) by 460.7% during the second quarter, now holding 23,063 shares valued at approximately $2.92 million. Teleflex, a medical technology company, recently exceeded earnings expectations with $1.76 EPS and $570.33 million in revenue, and analysts maintain a consensus "Hold" rating with an average price target of $152.90. The company also declared a quarterly dividend of $0.34 per share.
Teleflex Incorporated (TFX) Stock Analysis: Potential 23% Upside Amid Strong Revenue Growth
Teleflex Incorporated (TFX), a prominent healthcare company specializing in medical instruments, shows a potential upside of 23.31% and strong revenue growth of 28.90%. Despite a negative trailing P/E ratio, a positive forward P/E and an average analyst target price of $153.55 suggest confidence in its future performance. The company's financial health is bolstered by $179.54 million in free cash flow, though its high dividend payout ratio warrants attention.
Bank of America Corp DE Invests $61.16 Million in Teleflex Incorporated $TFX
Bank of America Corp DE has invested approximately $61.16 million in Teleflex Incorporated, acquiring 482,457 shares, which represents a 1.14% stake in the medical technology company. This investment comes as Teleflex exceeded its quarterly earnings and revenue expectations, despite analysts maintaining a generally cautious "Hold" rating for the stock. Institutional investors collectively own a significant 95.62% of Teleflex.
Teleflex Inc. stock edges higher as FY 2026 guidance and dividend underpin valuation
Teleflex Inc. (TFX) stock edged higher after strong Q2 2026 results showed revenue up 28.9 percent to USD 570.33 million, surpassing analyst estimates. The company provided FY 2026 EPS guidance of USD 6.90 to USD 7.20 and declared a quarterly dividend of USD 0.34 per share, offering a modest yield. Analysts maintain a "Hold" recommendation, with an average price target suggesting an 18.5 percent upside potential.
What Is Drawing Attention To Teleflex (TFX)?
Teleflex (TFX) is gaining attention following the appointment of former Medtronic executive Sean M. Salmon to its board, amidst recent product news and fluctuating short-term stock performance. The company's shares are considered 15% undervalued, priced at US$130.30 against a fair value of $153.55, driven by anticipated value creation from portfolio optimization and potential segment sales. However, concerns remain regarding UroLift trends and integration risks with Biotronik VI.
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Teleflex Incorporated has appointed Sean M. Salmon, a veteran medical technology executive with over three decades of global leadership experience, to its Board of Directors, effective September 8, 2026. Salmon, who previously held senior roles at Medtronic plc, will also serve on Teleflex's Growth and Operating Committee. His appointment aims to enhance the Board's strategic capabilities and support the company's ongoing strategic transformation and value creation.
Director Sean Salmon receives Teleflex (NYSE: TFX) stock and options
Teleflex Inc. (TFX) director Sean Salmon was granted 674 shares of common stock as a Restricted Stock Unit Award and stock options for 4,444 shares, both vesting 100% on the one-year anniversary of the September 8, 2026 grant date. The stock options have an exercise price of $137.00 per share and expire on September 8, 2036. These equity awards directly increase his stake in the company.
People on the Move: Sean M. Salmon Joins Teleflex Board of Directors
Teleflex Incorporated has appointed Sean M. Salmon to its Board of Directors, effective September 8, 2026. Salmon, an industry veteran with over 20 years of medical technology leadership at Medtronic, will also serve on the Growth and Operating Committee. His extensive experience in driving growth and profitability across medical technology businesses is expected to significantly benefit Teleflex's strategic priorities and shareholder value.
Teleflex appoints former Medtronic executive to board By Investing.com
Teleflex Incorporated has appointed Sean M. Salmon, a former Medtronic executive with over 20 years of experience, to its Board of Directors. Salmon previously led Medtronic's Cardiovascular Portfolio, which generated $12.5 billion in fiscal 2025 revenue. His appointment expands Teleflex's board to nine directors, enhancing the company's strategic transformation efforts.
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Teleflex Incorporated (NYSE:TFX) has announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Salmon brings over 30 years of global leadership experience in the medical device and pharmaceutical industries, including more than two decades at Medtronic plc where he held various senior roles. His appointment is expected to bolster the Board's expertise in strategic growth and operational execution as Teleflex continues its strategic transformation.
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Teleflex Incorporated has appointed Sean M. Salmon, a veteran medical technology executive with over three decades of global leadership experience, to its Board of Directors. Mr. Salmon previously spent more than 20 years at Medtronic plc, most recently as Executive Vice President and President of its Cardiovascular Portfolio. His appointment is expected to bolster Teleflex's strategic priorities and governance, with him also serving on the Growth and Operating Committee.
Teleflex Incorporated Announces Appointment of Sean M. Salmon to Board of Directors and to the Growth and Operating Committee, Effective September 8, 2026
Teleflex Incorporated has announced the appointment of Sean M. Salmon to its Board of Directors and to the Growth and Operating Committee, effective September 8, 2026. Salmon brings extensive experience from his 21-year career at Medtronic plc, where he held various executive leadership roles in cardiovascular and diabetes sectors, as well as prior positions at C.R. Bard Inc. and Johnson & Johnson. He currently provides business consulting through Zamboni Holdings, LLC and serves on the board of Adagio Medical Holdings Inc.
Teleflex Sinks ahead of Copenhagen Show
Teleflex Incorporated (NYSE: TFX) shares fell on Friday despite the company announcing it will showcase innovative medical technologies, including the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System, at CIRSE 2026 in Copenhagen. The Dynetic™-35 system, supported by the BIONETIC-TRA study, is designed for treating atherosclerotic iliac artery lesions using a trans-radial approach, offering an alternative to traditional femoral artery access. The study showed a 100% procedural success rate via radial access, addressing challenges with complex femoral access cases.
Is TFX a Buy Now as Valuation Improves but Execution Risks Remain?
Teleflex (TFX) presents a more attractive valuation with its stock trading below industry averages and its five-year median. The company has also improved its financial standing through debt reduction and share repurchases, and raised its 2026 earnings guidance. However, the investment case is tempered by ongoing execution risks including slower integration of its Vascular Intervention business, unfinished divestitures, and margin pressures from competition and tariffs.
Needham raises Teleflex stock price target on Freesolve potential
Needham raised its price target for Teleflex Inc. (NYSE:TFX) to $170 from $159, maintaining a Buy rating, due to the potential of its Freesolve product. The firm anticipates Freesolve, a novel coronary scaffold, to significantly boost international sales by 2028 and contribute 1-2% to annual revenue growth. This outlook comes as Teleflex also reported strong Q2 2026 financial results, exceeding revenue and EPS expectations.
Needham Adjusts Price Target on Teleflex to $170 From $159, Maintains Buy Rating
Needham has increased its price target for Teleflex (TFX) from $159 to $170, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the analyst firm on the medical technology company.
Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?
Teleflex (TFX) recently sold its OEM business for $1.5 billion, significantly reducing its debt and improving its balance sheet. This strategic move led the company to raise its 2026 adjusted earnings outlook, despite cutting its revenue growth forecast. While capital allocation benefits are clear, the company still faces margin pressure and a pending divestiture of its Acute Care and Interventional Urology businesses.
Teleflex stock holds recent gains as INGENYX carve-out reshapes its medtech profile
Teleflex stock has seen a 5% gain over the past year, outperforming its industry, driven by its strategic carve-out of the Medical OEM unit into an independent company, INGENYX. This move allows Teleflex to focus on its core interventional and surgical product lines, supported by a strong long-term earnings growth estimate of 20.7% and a history of beating analyst expectations. The company's performance, particularly in its Arrow vascular access portfolio, positions it as a resilient medtech investment despite broader market volatility.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares advanced 2.87% on Friday, closing at $138.83, outperforming the broader market as the S&P 500 Index and Dow Jones Industrial Average also saw gains. The company's stock is currently 4.26% below its 52-week high of $145.00, reached earlier in August.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) stock rose 2.99% on Wednesday, closing at $135.86, outperforming the broader market indexes like the S&P 500 and Dow Jones Industrial Average. This increase ended a three-day losing streak for the company's shares. The positive performance occurred during an overall strong trading session for the stock market.
Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) stock fell 2.99% on Monday, closing at $133.07, and underperformed major indices like the S&P 500 and Dow Jones Industrial Average, which also saw declines. This marks the second consecutive day of losses for the company's stock.
Will Teleflex’s (TFX) Lowered 2026 Earnings Guidance and Margin Pressures Redefine Its Portfolio Story?
Teleflex reported Q2 2026 results with higher sales but lower net income, topping revenue and non-GAAP earnings expectations while cutting its 2026 earnings guidance. The lowered guidance, coupled with integration and margin pressures, challenges the investment narrative built around acquisitions and portfolio optimization. Investors are now focused on whether integration progress and cost discipline can become a near-term earnings catalyst for the company.
311,349 Shares in Teleflex Incorporated $TFX Purchased by Diamond Hill Capital Management LLC Investment Advisor
Diamond Hill Capital Management LLC purchased 311,349 shares of Teleflex Incorporated (NYSE:TFX) in Q2, valued at approximately $39.5 million, giving them a 0.70% stake. Teleflex exceeded Q2 earnings expectations, reporting $1.76 EPS against a $1.28 consensus and revenues of $570.3 million, a 28.9% year-over-year increase, and has forecasted fiscal 2026 EPS between $6.90 and $7.20. Despite a consensus "Hold" rating from analysts, other institutional investors have also adjusted their holdings in the medical technology company.
Teleflex Incorporated (NYSE:TFX) Receives Average Rating of "Hold" from Analysts
Teleflex Incorporated (NYSE:TFX) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $151.80. The company recently reported strong quarterly results, exceeding EPS and revenue expectations, and provided fiscal 2026 EPS guidance of $6.90 to $7.20. Institutional investors own a significant portion of Teleflex's shares, and the company maintains a quarterly dividend of $0.34 per share.
Assenagon Asset Management S.A. Invests $1.39 Million in Teleflex Incorporated $TFX
Assenagon Asset Management S.A. has acquired 10,974 shares of Teleflex Incorporated (NYSE:TFX), valued at approximately $1.39 million, making it a new position for the firm in the second quarter. Teleflex has shown strong financial performance, exceeding quarterly earnings expectations with an EPS of $1.76 and revenue of $570.33 million, a 28.9% increase year-over-year. The company maintains a consensus "Hold" rating from analysts with an average price target of $151.80 and recently announced a quarterly dividend of $0.34 per share.
Teleflex (TFX) Stock Looks Undervalued On Cash Flow But Overvalued On Sales
Teleflex (TFX) stock appears undervalued based on a Discounted Cash Flow (DCF) model, suggesting a 46.8% discount from its intrinsic value due to strong free cash flow and planned debt reduction and buybacks. However, the stock screens as overvalued on a Price/Sales (P/S) multiple compared to its fair ratio implied by fundamentals, despite being below the wider industry benchmarks. This mixed valuation highlights a discrepancy between its cash flow generation potential and market multiples, leaving its future direction dependent on successful execution of portfolio plans and cash generation.
Teleflex (TFX) Q2 2026 Earnings Call Transcript
Teleflex reported a 4.7% increase in pro forma adjusted constant currency revenue for Q2 2026, driven by strong Vascular and Surgical segment performance, despite Interventional segment integration challenges. The company completed a $1.5 billion OEM divestiture to fund debt reduction and share repurchases, and it raised its full-year adjusted EPS guidance due to lower interest expenses and share buybacks. Teleflex also highlighted the FDA approval of EZPLAZ and advancements in its Freesolve clinical trials, emphasizing a strategic shift toward core critical care and high-acuity markets.
First Trust Advisors LP Reduces Stock Position in Teleflex Incorporated $TFX
First Trust Advisors LP significantly reduced its stake in Teleflex Incorporated by 98.4% in Q1 2026, selling over 161,000 shares but retaining a small position. Despite this, institutional investors still hold a substantial 95.62% of the company's stock. Teleflex reported strong Q2 earnings, beating analyst estimates, and announced a quarterly dividend.
Teleflex Inc. stock outperforms competitors on strong trading day
Shares of Teleflex Inc. (TFX) increased by 2.08% to $136.32 on Wednesday, marking its second consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index rose by 0.26% and the Dow Jones Industrial Average fell by 0.04%.
Bank of America Corp DE Buys 27,004 Shares of Teleflex Incorporated $TFX
Bank of America Corp DE increased its stake in Teleflex Incorporated by 6.4% in the first quarter, acquiring an additional 27,004 shares, bringing its total holdings to 445,958 shares valued at $53.3 million. Institutional investors collectively own 95.62% of Teleflex. The company exceeded its quarterly earnings expectations with $1.76 EPS and $570.33 million in revenue, and analysts currently maintain a consensus "Hold" rating with an average price target of $151.80.
Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) stock declined by 1.47% on Monday, closing at $133.00, despite a generally poor trading session for the broader market. This marks the second consecutive day of losses for the company. The S&P 500 Index (SPX) fell 0.06% and the Dow Jones Industrial Average (DJIA) fell 0.11% on the same day.
TELEFLEX INCORPORATED : TRUIST SECURITIES RAISES TARGET PRICE TO $150 FROM $143
Truist Securities has increased its target price for Teleflex Incorporated (TFX.N) to $150 from $143. This update indicates a more positive outlook from the securities firm on the medical technology company's stock. The information was reported by Reuters.
Truist Securities Adjusts Price Target on Teleflex to $150 From $143, Keeps Hold Rating
Truist Securities has increased its price target for Teleflex (NYSE:TFX) to $150 from $143, while maintaining a "Hold" rating on the stock. This adjustment comes amidst other analyst activities, including RBC Capital Markets' assessment that Teleflex's 2027 framework is achievable and Needham raising its price target to $159. Teleflex recently reported its Q2 2026 earnings, showing an increase in adjusted EPS and revenue, and updated its full-year 2026 earnings guidance.
Teleflex Incorporated (TFX) Stock Analysis: Exploring a Promising 11.67% Upside Potential in the Healthcare Sector
Teleflex Incorporated (TFX) is a significant player in the healthcare sector, providing single-use medical devices, and analysts see an 11.67% upside potential for the stock. Despite robust revenue growth, the company faces challenges with negative EPS and a high dividend payout ratio, which investors should consider. Technical indicators suggest bullish momentum, trading above key moving averages, but a high RSI hints at potentially overbought conditions.
Teleflex Q2 Earnings Call Highlights
Teleflex reported Q2 revenue and adjusted earnings above expectations, driven by strong Vascular and Surgical business growth. However, the slower-than-anticipated integration of its Vascular Intervention acquisition impacted Interventional results. The company outlined plans for divestitures, debt reduction, and share repurchases, and updated its full-year 2026 outlook, lowering revenue growth but raising EPS guidance.
Teleflex Inc.: Entered Accelerated Share Repurchase Program With Truist Bank >TFX
Teleflex Inc. has announced that it has entered into an accelerated share repurchase program with Truist Bank. This program allows Teleflex to repurchase its own shares, typically indicating management's belief that the stock is undervalued.
Teleflex Incorporated (TFX) Stock Forecasts
Argus has raised its target price for Teleflex Incorporated (TFX) to $147.00. Teleflex, a manufacturer of hospital supplies and medical devices, is currently priced at $134.98. The report provides a summary of the company's operations and offers insights for potential investors.
Teleflex Inc.: To Repurchase Aggregate $250M of Co's Common Stock>TFX
Teleflex Inc. announced its intention to repurchase an aggregate of $250 million of its common stock. This move is typically seen as a way for a company to return value to shareholders and can indicate management's confidence in the company's future prospects. The repurchase program could impact the company's stock price and financial metrics.
Teleflex Inc. stock underperforms Friday when compared to competitors
Teleflex Inc. (TFX) shares dropped 2.82% on Friday, closing at $134.98, despite a positive trading day for the broader market with the S&P 500 and Dow Jones Industrial Average both rising. The company's stock is currently 6.91% below its 52-week high of $145.00, which was reached on August 6th.
Amundi Has $4.62 Million Stake in Teleflex Incorporated $TFX
Amundi increased its stake in Teleflex Incorporated (NYSE:TFX) by 325.2% in the first quarter, now holding 38,606 shares valued at approximately $4.62 million. Teleflex exceeded second-quarter expectations with adjusted EPS of $1.76 and revenue of $570.3 million, and raised its fiscal 2026 EPS guidance to $6.90–$7.20. Despite strong adjusted results and a declared quarterly dividend of $0.34 per share, GAAP EPS and net margin remained weak, leading analysts to maintain a "Hold" rating with a consensus price target of $148.90.
Teleflex Medical OEM relaunches as INGENYX
INGENYX, formerly Teleflex Medical OEM, has launched as an independent company after being acquired by Montagu and Kohlberg and carved out from Teleflex Inc. The company specializes in developing and manufacturing custom-engineered interventional catheters, sutures, and other advanced medical device technologies. This move positions INGENYX to expand its capabilities, accelerate innovation, and strengthen customer collaboration in the medical device manufacturing sector.
